<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>oncogenic pathway disruption &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/oncogenic-pathway-disruption/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 06 Sep 2025 13:26:42 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>oncogenic pathway disruption &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Revolutionizing Cancer Treatment: The Impact of MYCN and MDM2 Research</title>
		<link>https://bioengineer.org/revolutionizing-cancer-treatment-the-impact-of-mycn-and-mdm2-research/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 29 Jan 2025 17:46:28 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[molecular mechanisms in cancer therapy]]></category>
		<category><![CDATA[MYCN-MDM2 dual inhibition]]></category>
		<category><![CDATA[neuroblastoma targeted therapy]]></category>
		<category><![CDATA[oncogenic pathway disruption]]></category>
		<category><![CDATA[pediatric cancer treatment advancements]]></category>
		<guid isPermaLink="false">https://bioengineer.org/revolutionizing-cancer-treatment-the-impact-of-mycn-and-mdm2-research/</guid>

					<description><![CDATA[In recent years, the development and refinement of targeted therapies have illuminated new pathways in cancer treatment, particularly concerning the MYC oncogene family and its critical partner, MDM2. Researchers have increasingly focused on targeting the MYCN-MDM2 axis, a strategic move highlighting a potential turning point in our comprehension and treatment of neuroblastoma. Neuroblastoma, a prevalent [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">234937</post-id>	</item>
	</channel>
</rss>
